Q4 2025 Management View Peter Greenleaf, President, CEO & Director, opened the call announcing "strong LUPKYNIS sales in 2025 ...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar, ...

Clinical Trials suffer due to inherent inefficiencies in manual workflows built on fragmented systems. It's time for a ...

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...

Mayo Clinic, for its part, described the collaboration as its first strategic partnership of this scale with a global ...

Extensive peer-reviewed research has identified biologically active nutrients and biochemical intermediates that play ...

Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...

Q4 2025 earnings call: nsPFA clinical/regulatory timeline, Vybrance rollout, revenue trends, cash burn & outlook—read now.

Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosciences, Inc. (NASDAQ:JUNS)That alignment ...

Q4 2025 earnings call recap: pipeline milestones, PROTAC FDA/PDUFA timeline, 2026 data catalysts, and cash runway—read now.